Predictive Biotech, Inc. Announces a Beta Launch of Spine Deformity Molecular Diagnostic Test, Initially Focused on Scoliosis

Beta launch of new assay is the first of several spine related product introductions

SALT LAKE CITY, UT–(May 19, 2016)– Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, through its subsidiary Predictive Biotech, Inc., announces beta launch of a new molecular diagnostic assay developed to predict the severity of spine deformities and syndromes.

Eric Olson, Predictive Biotech’s President and CEO, stated, “We are pleased to move forward with our spinal deformity molecular diagnostic test and continue the development work on companion spinal treatment product candidates. Our commercialization strategy is to focus on collaboration with spine societies to jointly develop and improve the technologies to best meet surgeon members’ clinical needs. This new assay improves upon the work that was completed by individual surgeons from the Scoliosis Research Society (SRS) who participated in an unparalleled clinical study on scoliosis.”

Mike Schramm, Predictive Biotech’s Director of Intellectual Property, said, “In addition to the beta launch of a new ‘Spine Deformity Test’, initially focused on scoliosis, we look forward to the imminent grant of the US Patent application 20150127105 covering this technology.  The allowance of the ‘105 application was decided by the  United States Patent and Trademark Office’s Patent Trial and Appeal Board  and, we believe, supercede any other spinal deformity related molecular diagnostic tests, including molecular diagnostic for scoliosis. The claims of the ‘105 application are of such breadth that any treatment of any spine deformity disease falls within the scope of this patent.

Further, Schramm states, “We also believe this allowance will play a significant role in providing protection for Predictive’s planned commercial offering of other molecular diagnost tests and companion treatments. The ‘105 application builds upon other Predictive patents including 8,123,787, 8,641,738, and 20150337373.”

PRED’s subsidiary Predictive Biotech strives to provide its surgeon customers with the highest quality predictive diagnostics and treatment solutions that can ultimately benefit their patients.

For further information about PRED, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, and

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (OTC PINK: PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.